Evergreening isn’t just a legal tactic—it’s a business strategy designed to delay competition, extend exclusivity, and protect revenue streams long after the original patent estate should have expired.
And if you’re still reacting to drug patent filing…

Pfizer’s Keytruda, also known as pembrolizumab, received initial FDA approval on September 4, 2014, for use in treating… https://www.Drugchatter.com/chat/37536/can-you-recall-the-initial-fda-approval-year-for-keytruda/

The patent cliff isn’t a surprise anymore. The real question is: who moves first?
In pharma, the “patent cliff” has become less of an event and more of a calendar. Everyone knows the date when exclusivity ends. Fewer companies are prepared for the oper…

OpenAI’s GPT just took a swing at one of the most stubborn bottlenecks in pharma: the patent cliff.
DrugPatentWatch’s latest breakdown of OpenAI’s GPT–Rosalind work reads like a case study in what happens when generative AI stops being a “productivity …

Predict the Attack: How to Forecast Paragraph IV Filings and Neutralize “Skinny Label” Threats
In pharma, the most expensive moment isn’t when a generic launches—it’s when you didn’t see the challenge coming.
Paragraph IV drug patent challenges are oft…

Your drug’s “patent life” isn’t one number—it’s a moving target across the GCC. Here’s how to know exactly how long protection really lasts.
If you’re launching a product—or defending one—your timeline can’t be built on guesswork. In the GCC, “how long…

Unlocking the Hidden Timeline: How Long Do Drug Patents Last in the GCC?
Imagine investing millions into developing a groundbreaking medication, only to find out that your exclusive rights could expire sooner than expected, or worse, that your competit…

Your competitor doesn’t have to “win” to slow you down.
In pharma, the race isn’t only about who invents the next blockbuster—it’s also about who can keep today’s revenue streams alive long enough to outlast the next wave. And one of the most common (a…